176 related articles for article (PubMed ID: 34452183)
1. Preclinical Toxicity and Safety of MM-129-First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer.
Hermanowicz JM; Kalaska B; Pawlak K; Sieklucka B; Miklosz J; Mojzych M; Pawlak D
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452183
[TBL] [Abstract][Full Text] [Related]
2. MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer.
Hermanowicz JM; Pawlak K; Sieklucka B; Czarnomysy R; Kwiatkowska I; Kazberuk A; Surazynski A; Mojzych M; Pawlak D
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206937
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
[TBL] [Abstract][Full Text] [Related]
4. Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers.
Li G; Yu K; Li F; Xu K; Li J; He S; Cao S; Tan G
J Ethnopharmacol; 2014 Apr; 153(2):521-30. PubMed ID: 24631140
[TBL] [Abstract][Full Text] [Related]
5. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
6. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.
Zhao L; Li C; Liu F; Zhao Y; Liu J; Hua Y; Liu J; Huang J; Ge C
Onco Targets Ther; 2017; 10():2115-2126. PubMed ID: 28442920
[TBL] [Abstract][Full Text] [Related]
7. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
[TBL] [Abstract][Full Text] [Related]
8. Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo.
Trendowski M; Wong V; Wellington K; Hatfield S; Fondy TP
In Vivo; 2014; 28(6):1021-31. PubMed ID: 25398795
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120.
Kulikov A; Shipaeva E; Dmitrieva A; Batrak V; Shipunov G; Guy C; Smith J; Zhang R; Zhang M; Duan J; Chestukhin A; Barbashov S; Samsonov M; Lavrovsky Y
Front Pharmacol; 2021; 12():723038. PubMed ID: 34456733
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of β-2-himachalen-6-ol in colon cancer is mediated through its inhibition of the PI3K and MAPK pathways.
Daaboul HE; Daher CF; Bodman-Smith K; Taleb RI; Shebaby WN; Boulos J; Dagher C; Mroueh MA; El-Sibai M
Chem Biol Interact; 2017 Sep; 275():162-170. PubMed ID: 28782499
[TBL] [Abstract][Full Text] [Related]
13. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent.
Wang W; Liao L; Wang Y; Li H; Suo Z; Long K; Tang P
Cancer Biol Ther; 2018; 19(11):1015-1022. PubMed ID: 29799306
[No Abstract] [Full Text] [Related]
15. Acute toxic effects of ruthenium (II)/amino acid/diphosphine complexes on Swiss mice and zebrafish embryos.
Mello-Andrade F; Cardoso CG; Silva CRE; Chen-Chen L; Melo-Reis PR; Lima AP; Oliveira R; Ferraz IBM; Grisolia CK; Almeida MAP; Batista AA; Silveira-Lacerda EP
Biomed Pharmacother; 2018 Nov; 107():1082-1092. PubMed ID: 30257320
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy and safety assessment of nano-oxaliplatin oral formulation prepared by novel Fat Employing Supercritical Nano System, the FESNS®.
Kim YH; Lee SJ; Lee SH; Hahn M
Pharm Dev Technol; 2012; 17(6):677-86. PubMed ID: 23216046
[TBL] [Abstract][Full Text] [Related]
17. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
18. Comparative toxicity evaluation of targeted anticancer therapeutics in embryonic zebrafish and sea urchin models.
Babic T; Dinic J; Buric SS; Hadzic S; Pesic M; Radojkovic D; Rankov AD
Acta Biol Hung; 2018 Dec; 69(4):395-410. PubMed ID: 30587022
[TBL] [Abstract][Full Text] [Related]
19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
